Proactive Investors - Run By Investors For Investors

Admedus commences animal trials for heart valve device

The heart valve device could be a game-changer in the US$3.5 billion market.
heart puzzle being dissected with tweezers
The trial will involve multiple animals

Admedus Ltd (ASX:AHZ) has commenced animal trials by completing the first successful live implantation of its unique single-piece aortic heart valve.

This represents a key milestone in the development of its patented transcatheter aortic valve replacement (TAVR) project.

Admedus has partnered with a European lab to examine the safety and feasibility of the unique valve in live sheep.

The first single-piece valve was implanted today officially marking the start of the trial period, which is expected to last for around five months.

READ: Admedus board members stand with shareholders and buy shares

Admedus’s CEO Wayne Paterson said: “Today is a significant step for the TAVR project as we move into the next stage of development.

“It was exciting to observe the first-ever of our unique single-piece valves being placed inside a living heart.

“These experiments are being conducted by global leaders in the field and will provide critical insight for our development team as we accelerate towards product commercialisation.”

READ: Admedus signs exclusive distribution agreement in Italy for its unique heart tissue product

Momentum continues to build after recent lab testing of multiple valves were run out to 400 million cycles, which is roughly 10 years of human use.

Whilst the Admedus valves remained functional after 400 million cycles, the competitor valve showed significant fatigue at 250 million cycles.

Paterson added: “This device has the potential to be a game-changer for patients, the Company and the US$3.5 billion TAVR market.”

View full AHZ profile View Profile

Admedus Ltd Timeline

November 01 2018

Related Articles

surgeons working
September 03 2018
Chief executive Steve Couldwell also told investors the regenerative medicines specialist had identified a number of potential new commercial opportunities it was “actively pursuing”
blood samples in test tubes
October 26 2018
The NYSE-listed company has designed a routine blood test to screen for colorectal and prostate cancers that reduces the need for more invasive colonoscopies and biopsies
September 18 2018
The company is utilising technology and big data to tackle the growing healthcare crisis and personalise treatment options for preventative care.

© Proactive Investors 2018

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use